Your Weekly Peptide Intelligence
Every Sunday, we distill the week's most important research into a single curated briefing. Five to ten minutes. Zero fluff.
The Dose Is Only Half the Protocol
VCT220’s 16-week weight-loss result is strong, but its titration data reveal the more practical lesson: schedule can shape tolerability without sacrificing much efficacy.
Read issue →The Endpoint Changes the Story
BGM0504, oral semaglutide, and peceleganan show why promising signals still need the right comparator, endpoint, and clinical context.
Read issue →The Formulation Is Part of the Medicine
DD01’s liver-fat signal, a split GLP-1 verdict in Parkinson’s, and a longer-lasting thymosin beta-4 candidate show why formulation and endpoints matter.
Read issue →Mental Health, Muscle, and the Peptide Power Struggle
GLP-1 drugs show real anxiolytic effects, amylin therapies emerge as the next weight-loss frontier, survodutide targets dangerous visceral fat, and FDA scientists challenge the peptide access push.
Read issue →The GLP-1 Multi-System Story Gets Louder
Six articles, five GLP-1 stories — tirzepatide beats semaglutide at scale, dulaglutide shows neuroprotection in MS, surgical safety questions mount, and thymosin alpha-1 rebuilds immunity after chemo.
Read issue →The GLP-1 Landscape Just Shifted
Four major studies in one week redraw the metabolic medicine map — tirzepatide vs semaglutide, amycretin's 24% weight loss, semaglutide in psychiatric populations, and retatrutide's phase 3 Lancet data.
Read issue →The Muscle Problem Gets a Mechanistic Answer
A JCI Insight study shows ketone esters prevent semaglutide-induced muscle loss by protecting mitochondrial function — without compromising fat loss.
Read issue →The Weekly Dose: GLP-1s Go Cardiac, Peptide Purity Hits Crisis Point
GLP-1 agonists show a 33% atrial fibrillation risk reduction, independent labs report a third of peptide samples failing quality checks, and retatrutide data reveals fat tissue reprogramming at the cellular level.
Read issue →New Horizons: Peptides, GLP-1s, and the FDA Big Shift
From FDA rule changes to oral GLP-1 breakthroughs and the most important peptide research of the year, here is what actually matters.
Read issue →The Weekly Dose: FDA Peptide Review, Genomic Peptides, and Mitochondrial Signaling
This week's developments in peptide therapeutics: FDA advisory committee meeting, genomic analysis of GHK-Cu, and mitochondrial peptide MOTS-c.
Read issue →The Oral GLP-1 Era Begins — And Five Other Things You Need to Know
The first no-strings-attached GLP-1 pill got approved, the FDA is reconsidering 12 peptides, and BPC-157's evidence base just got quantified. Your weekly briefing.
Read issue →